全エクソームシーケンス（WES）の世界市場-2022-2029年

市場力学

世界の全エクソームシーケンス（WES）市場の成長は、希少疾患の診断需要の増加、ゲノミクスと次世代シーケンサー分野の研究開発の高まり、個別化医療の需要の高まりなど、いくつかの要因によって推進されています。

全エクソームシーケンス（WES）の採用が増加していることが、世界市場の成長を促進しています。

がんをはじめとするさまざまな慢性疾患の予測、治療、モニタリングのための次世代シーケンサー手法の採用が増加しており、世界的に市場の成長を後押ししています。がんのエクソーム配列決定により、腫瘍の進行に寄与するコーディング変異に関する貴重な情報が得られます。エクソームはゲノムの2%未満であるため、がんエクソームシーケンスは全ゲノムシーケンスに代わる費用対効果の高い手法です。また、エクソームシーケンスでは、全ゲノムアプローチと比較して、より便利なデータセットが得られます。さらに、全エクソームシーケンス技術に関連する低コストと高速性、全エクソームシーケンス技術の技術的進歩、世界の主要研究機関の戦略的提携も、全エクソームシーケンス市場の成長を後押ししています。例えば、2021年5月、Baylor Genetics社はRapid Trio Whole Exome Sequencingを導入し、その納期を7日から5日に短縮しています。さらに、ニューヨーク大学の研究によると、Whole Exome Sequencing Predicts Whether Patients Respond to Cancer Immunotherapy（全エクソームシーケンスにより、患者ががん免疫療法に反応するかどうかが予測される）となっています。

熟練した人材の不足と政府支援の剥奪が、Whole Exome Sequencing（WES）の世界市場成長のハードルとなっています。

しかし、熟練した専門家の不足と政府補助金への高い依存度が、全エクソームシーケンス市場の成長を抑制しています。

業界の分析

世界の全エクソームシーケンス（WES）市場レポートでは、Porter`s Five Force、イノベーション、新製品発表、価格分析、Etcなどの様々な業界要因に基づいて、市場の詳細な分析を提供します。

COVID-19のインパクト分析

COVID-19はWhole Exome Sequencing（WES）市場に新たな機会を提供しました。例えば、COVID-19はデジタルケアという新しい現実を実践するよう促しています。パンデミック時には、中断を最小限に抑え、ヘルスケアへのアクセスの低下を最小限に抑えるためのバーチャルケア介入が急務であることが明らかになり、特定の遺伝子型と感染リスクとの関係を特定するためのシーケンス手法に注目が集まりました。さらに、パンデミック後、デジタルヘルスケアソリューションへの資金提供が増加し、世界の全エクソームシーケンス［WES］市場の成長にプラスの影響を及ぼしています。

世界の全エクソームシーケンス［WES］市場レポートでは、約40以上の市場データ表、45以上の図、200ページ（概算）の範囲でのアクセスを提供することになります。

目次

• 調査手法
• 調査目的および調査範囲

第2章 市場の定義と概要

第3章 エグゼクティブサマリー

第4章 市場の力学

• 市場影響要因
  • 促進要因
    • 採用の増加
    • 研究開発の活発化
  • 抑制要因
    • 熟練したプロフェッショナルの不足
  • ビジネスチャンス
  • 影響分析

第5章 産業分析

• ポーターのファイブフォース分析
• サプライチェーン分析
• 規制分析

第6章 COVID-19の分析

• COVID-19の市場分析
  • COVID-19以前の市場シナリオ
  • COVID-19の現在の市場シナリオ
  • COVID-19の後、または将来のシナリオ
• COVID-19の中での価格ダイナミクス
• 需要-供給スペクトラム
• パンデミック時の市場に関連する政府の取り組み
• メーカーの戦略的取り組み
• まとめ

第7章 製品・サービス別

• システム
• キット
  • ライブラリー調製キット
  • ターゲットエンリッチメントキット
  • その他
• サービス内容
  • シーケンシングサービス
  • データ解析（バイオインフォマティクス）サービス
  • その他サービス

第8章 技術別

• 第2世代シーケンシング
  • 合成法シーケンシング（SBS）
  • ハイブリダイゼーション・ライゲーションシーケンシング（SBL）
• 第3世代シーケンサー

第9章 アプリケーション別

• 創薬・医薬品開発
• 診断薬
• 個別化医療
• その他

第10章 地域別

• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • イタリア
  • スペイン
  • その他欧州
• 南米
  • ブラジル
  • アルゼンチン
  • その他の南米地域
• アジア太平洋地域
  • 中国
  • インド
  • 日本
  • オーストラリア
  • その他アジア太平洋地域
• 中東・アフリカ地域

第11章 競合情勢

• 主な展開と戦略
• 企業シェア分析
• 製品ベンチマーク

第12章 企業プロファイル

• Agilent Technologies Inc.
  • 企業概要
  • 製品ポートフォリオと説明
  • 主なハイライト
  • 財務概要
• Illumina Inc.
• Bio-Rad Laboratories Inc.
• Macrogen Inc.
• Beijing Genomics Institute
• Ambry Genetics Corp.
• Eurofins Scientific Group
• F. Hoffmann-La Roche AG
• GENEWIZ Inc.
• Pacific Biosciences of California Inc.

第13章 DataM

Market Overview

Whole Exome Sequencing [WES] Market is expected to grow at a CAGR of 18.6% during the forecasting period (2022-2029).

Whole exome sequencing is a commonly used next-generation sequencing (NGS) procedure that involves sequencing protein-coding regions of the genome. The human exome represents less than 2% of the genome but contains about 85% known disease-related variants, making this method a cost-effective alternative to whole-genome sequencing. Exome sequencing is widely used to identify and determine genetic variants causing various diseases, such as Miller syndrome and Alzheimer's disease. It also provides a cost-effective screening approach for the diagnosis of genetic disorders. It presents a less resource-intensive alternative to whole-genome sequencing in several applications, including drug discovery and development.

Market Dynamics

The global whole exome sequencing [WES] market growth is driven by several factors, such as increasing demand for the diagnosis of rare diseases, rising research and development in the genomics and next-generation sequencing field, and growing demand for personalized medicine.

The increasing adoption of Whole Exome Sequencing [WES] propels the global market growth.

The rising adoption of next-generation sequencing methods for predicting, treating, and monitoring various chronic diseases, such as cancer, is boosting the market's growth globally. Sequencing the cancer exome provides valuable information about the coding mutations contributing to tumor progression. As the exome represents less than 2% of the genome, cancer exome sequencing is a cost-effective alternative to whole-genome sequencing. Exome sequencing also produces a more convenient data set compared to whole-genome approaches. In addition, the low cost and high speed associated with whole-exome sequencing technology, technological advancements in whole-exome sequencing techniques, and strategic alliances among leading research institutes globally, are also driving the growth of the whole-exome sequencing market. For instance, In May 2021, Baylor Genetics introduced Rapid Trio Whole Exome Sequencing, reducing its turnaround time from seven to five days. Moreover, according to the New York University research, Whole Exome Sequencing Predicts Whether Patients Respond to Cancer Immunotherapy.

The lack of skilled personnel and deprived government support are hurdles to the global Whole Exome Sequencing [WES] market growth.

However, the lack of skilled professionals and high dependability on government grants are restraining the growth of the whole-exome sequencing market.

Industry analysis.

The global whole exome sequencing [WES] market report will provide an in-depth analysis of the market based on various industry factors such as porter`s five forces, innovations, new product launches, pricing analysis, Etc.

COVID-19 Impact Analysis

COVID-19 has provided the Whole Exome Sequencing [WES] market with emerging opportunities. For instance, COVID-19 has encouraged us to practice the new reality of digital care. During the pandemic, it was revealed that there is an urgency for virtual care interventions to reduce the interruptions to a minimum and to minimize compromised access to healthcare, which caused increased focus on the sequencing methods for identification of relationships between particular genotypes with the risk of infection. Furthermore, post-pandemic, there is a rise in funding for digital healthcare solutions, positively impacting the global Whole Exome Sequencing [WES] market growth.

Segment Analysis

The Whole Exome Sequencing [WES] application in personalized medicine is predicted to have the largest global market share during the forecast period (2022-2029).

Personalized medicine is expected to grow at the highest rate during the forecast period (2022-2029). Since it aims to provide tailor-made therapies to individual patients, depending on the molecular basis of the disease, it has become popular over recent years. The rising demand for personalized medicine has created tremendous opportunities in genetic medicine. To exploit these opportunities, novel diagnostic and therapeutic technologies must be developed, resulting in the rapid expansion of the global whole exome sequencing market. Growing research & development in precise detection and diagnosis of the disease is expected to minimize the cost of treating chronic conditions. Advancements in whole genome sequencing and molecular diagnostics have given health sciences a better understanding of the precise nature of diseases and pathways to develop personalized treatments.

Geographical Analysis

The North American region commands the global Whole Exome Sequencing [WES] market during the forecast period (2022-2029).

North America is dominating the global whole exome sequencing [WES] market, accounting for the largest market share in 2021. Because of the increasing prevalence of genetic and chronic disorders, such as Cancer, the aging population, increasing demand for targeted and personalized medicine, advanced technological healthcare framework, and favorable government initiatives. For instance, the American Hospital Association estimated that by 2030 around 170 million Americans will be suffering from at least one chronic disease. Furthermore, Cancer is second among the leading cause of death in the U.S. Every year in the United States, over 1.6 million people are diagnosed with Cancer, and nearly 600,000 die from it, making it the second leading cause of death. In addition, rising research activities and investment is estimated to drive industry size in the coming years. Investments in medical health R&D are on a surge, with an 11.1% growth in spending registered between 2019 to 2020. Moreover, United States (U.S.) medical and health research and development (R&D) investment reached $245.1 billion in 2020.

Competitive Landscape

The global whole exome sequencing market is highly competitive with many players. Some of the major players in the market are Illumina Inc., Bio-Rad Laboratories Inc., Agilent Technologies Inc., Macrogen Inc., Beijing Genomics Institute, Ambry Genetics Corp., Eurofins Scientific Group, F. Hoffmann-La Roche AG, GENEWIZ Inc., Pacific Biosciences of California Inc., among others. The key players are adopting various growth strategies such as product launches, mergers & acquisitions, partnerships, and collaborations, contributing to the growth of the Whole Exome Sequencing [WES] market globally. For instance, on 5 May 2022, Illumina partnered with Deerfield Management to accelerate drug development. Also, on August 03, 2022, Bio-Rad Acquired Curiosity Diagnostics.

Agilent Technologies, Inc.

Overview:

Agilent Technologies, Inc. is a leading life sciences company that provides instruments, software, services, and consumables for laboratory workflow. Agilent was established in 1999 and is headquartered in Santa Clara, California, United States.

Product Portfolio:

Agilent Technologies, Inc.'s product portfolio for Whole Exome Sequencing [WES] has a SureSelect Human All Exon V8, SureSelect Focused Exome, SureSelect Clinical Research Exome V2 and SureSelect non-human Exomes.

The global whole exome sequencing [WES] market report would provide access to approximately 40+ market data tables, 45+ figures, and in the range of 200 (approximate) pages.

Table of Contents

Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

4. Market Dynamics

• 4.1. Market Impacting Factors
  • 4.1.1. Drivers
    • 4.1.1.1. The Increasing Adoption
    • 4.1.1.2. Increased Research and Development
  • 4.1.2. Restraints
    • 4.1.2.1. Lack of Skilled Professional
  • 4.1.3. Opportunity
  • 4.1.4. Impact Analysis

5. Industry Analysis

• 5.1. Porter's Five Forces Analysis
• 5.2. Supply Chain Analysis
• 5.3. Regulatory Analysis

6. COVID-19 Analysis

• 6.1. Analysis of Covid-19 on the Market
  • 6.1.1. Before COVID-19 Market Scenario
  • 6.1.2. Present COVID-19 Market Scenario
  • 6.1.3. After COVID-19 or Future Scenario
• 6.2. Pricing Dynamics Amid Covid-19
• 6.3. Demand-Supply Spectrum
• 6.4. Government Initiatives Related to the Market During Pandemic
• 6.5. Manufacturer's Strategic Initiatives
• 6.6. Conclusion

7. By Product & Services

• 7.1. Introduction
  • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product & Services Segment
  • 7.1.2. Market Attractiveness Index, By Product & Services Segment
• 7.2. Systems
  • 7.2.1. Introduction
  • 7.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
• 7.3. Kits
  • 7.3.1. Library Preparation Kits
  • 7.3.2. Target Enrichment Kits
  • 7.3.3. Others
• 7.4. Services
  • 7.4.1. Sequencing Services
  • 7.4.2. Data Analysis (Bioinformatics) Services
  • 7.4.3. Others Services

8. By Technology

• 8.1. Introduction
  • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Technology Segment
  • 8.1.2. Market Attractiveness Index, By Technology Segment
• 8.2. Second-generation Sequencing
  • 8.2.1. Introduction
  • 8.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 8.2.3. Sequencing by Synthesis (SBS)
  • 8.2.4. Sequencing by Hybridization and Ligation (SBL)
• 8.3. Third-generation Sequencing

9. By Application

• 9.1. Introduction
  • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application Segment
  • 9.1.2. Market Attractiveness Index, By Application Segment
• 9.2. Drug Discovery and Development
  • 9.2.1. Introduction
  • 9.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
• 9.3. Diagnostics
• 9.4. Personalized Medicine
• 9.5. Others

10. By Region

• 10.1. Introduction
  • 10.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
  • 10.1.2. Market Attractiveness Index, By Region
• 10.2. North America
  • 10.2.1. Introduction
  • 10.2.2. Key Region-Specific Dynamics
  • 10.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product & Services
  • 10.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Technology
  • 10.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
  • 10.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 10.2.6.1. The U.S.
    • 10.2.6.2. Canada
    • 10.2.6.3. Mexico
• 10.3. Europe
  • 10.3.1. Introduction
  • 10.3.2. Key Region-Specific Dynamics
  • 10.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product & Services
  • 10.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Technology
  • 10.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
  • 10.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 10.3.6.1. Germany
    • 10.3.6.2. The U.K.
    • 10.3.6.3. France
    • 10.3.6.4. Italy
    • 10.3.6.5. Spain
    • 10.3.6.6. Rest of Europe
• 10.4. South America
  • 10.4.1. Introduction
  • 10.4.2. Key Region-Specific Dynamics
  • 10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product & Services
  • 10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Technology
  • 10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
  • 10.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 10.4.6.1. Brazil
    • 10.4.6.2. Argentina
    • 10.4.6.3. Rest of South America
• 10.5. Asia Pacific
  • 10.5.1. Introduction
  • 10.5.2. Key Region-Specific Dynamics
  • 10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product & Services
  • 10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Technology
  • 10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
  • 10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 10.5.6.1. China
    • 10.5.6.2. India
    • 10.5.6.3. Japan
    • 10.5.6.4. Australia
    • 10.5.6.5. Rest of Asia Pacific
• 10.6. Middle East and Africa
  • 10.6.1. Introduction
  • 10.6.2. Key Region-Specific Dynamics
  • 10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product & Services
  • 10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Technology
  • 10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application

11. Competitive Landscape

• 11.1. Key Developments and Strategies
• 11.2. Company Share Analysis
• 11.3. Product Benchmarking

12. Company Profiles

• 12.1. Agilent Technologies Inc.
  • 12.1.1. Company Overview
  • 12.1.2. Product Portfolio and Description
  • 12.1.3. Key Highlights
  • 12.1.4. Financial Overview
• 12.2. Illumina Inc.
• 12.3. Bio-Rad Laboratories Inc.
• 12.4. Macrogen Inc.
• 12.5. Beijing Genomics Institute
• 12.6. Ambry Genetics Corp.
• 12.7. Eurofins Scientific Group
• 12.8. F. Hoffmann-La Roche AG
• 12.9. GENEWIZ Inc.
• 12.10. Pacific Biosciences of California Inc.

LIST NOT EXHAUSTIVE

13. DataM

• 13.1. Appendix
• 13.2. About Us and Services
• 13.3. Contact Us